Form 4: HeartSciences CEO Andrew Simpson Granted Significant Equity Awards Tied to FDA Clearance

HeartSciences Inc. has granted its Chairman, President, and CEO, Andrew Simpson, 275,000 stock options and 68,750 Restricted Stock Units, with vesting largely contingent on future FDA regulatory clearance of its MyoVista wavECG device or AI-ECG algorithm.

Summary

• Andrew Simpson, Chairman of the Board, President, and Chief Executive Officer of HeartSciences Inc., was granted 275,000 stock options and 68,750 Restricted Stock Units (RSUs) effective July 9, 2025.
• The stock options have an exercise price of $4.37 per share and will vest one-third on the 12-month anniversary of the effective date, with an additional 8.333% vesting quarterly thereafter, completing full vesting by July 9, 2028.
• Both the stock options and RSUs include accelerated vesting provisions upon the earlier of U.S. FDA regulatory clearance for the MyoVista wavECG device or AI-ECG algorithm, or a Change of Control.
• The RSUs will vest immediately upon the earlier of FDA clearance of the MyoVista Device (including AI algorithm) or the MyoVista Insights platform together with the first AI algorithm.
• As of the filing date, the required regulatory clearance from the U.S. Food and Drug Administration has not been received.
• The stock options expire on July 9, 2035.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to the CEO, tied to critical regulatory milestones, indicates a strong commitment to future product success and aligns management incentives with shareholder value. The explicit mention that FDA clearance has not yet been received introduces a known contingency, but the overall structure is positive for long-term alignment.

Positives

• The equity grants align the interests of the CEO, Andrew Simpson, with the long-term success and shareholder value creation of HeartSciences Inc.
• The performance-based vesting conditions, particularly the linkage to FDA clearance of key products (MyoVista wavECG device, AI-ECG algorithm, MyoVista Insights platform), incentivize the achievement of critical strategic milestones.
• The grant of 275,000 stock options and 68,750 RSUs represents a significant incentive package for the CEO.

Negatives

• The vesting of a substantial portion of the equity awards is contingent on future FDA regulatory clearance, which introduces uncertainty and risk.
• The issuance of these equity awards could lead to future share dilution upon exercise of options or settlement of RSUs.

Risks

• Regulatory clearance for the MyoVista wavECG device or AI-ECG algorithm from the U.S. Food and Drug Administration has not yet been received, which is a critical condition for accelerated vesting of the equity awards.
• The vesting of the equity awards is subject to Andrew Simpson's continued employment with the Issuer.

Future Outlook

The future outlook for the company's MyoVista wavECG device and AI-ECG algorithm is tied to obtaining U.S. FDA regulatory clearance, which is a key milestone for the accelerated vesting of executive equity awards.

Management Comments

• "These options were granted to the Reporting Person effective as of July 9, 2025 (the 'Effective Date'), pursuant to the approval of the compensation committee of the Issuer's board of directors."
• "As of the date of this filing, such regulatory clearance has not been received." (Referring to FDA clearance for MyoVista wavECG device or AI-ECG algorithm).

Industry Context

This grant reflects a common practice in the medical device and health technology industry where executive compensation is often tied to significant regulatory milestones, such as FDA clearance, which are critical for product commercialization and market entry. This aligns executive incentives with the achievement of key value-driving events in a highly regulated sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise/settlement of awards, but also potential for increased shareholder value if FDA clearance is achieved and products are commercialized successfully, aligning management incentives with shareholder interests.
• Employees: The grant to the CEO may set a precedent or reflect the company's overall compensation philosophy, potentially impacting employee morale and retention.

Next Steps

• Continued efforts by HeartSciences Inc. to obtain U.S. FDA regulatory clearance for its MyoVista wavECG device or AI-ECG algorithm.
• Monitoring of the vesting schedule for Andrew Simpson's stock options and RSUs, contingent on time and regulatory milestones.

Key Dates

Recommendation

Keywords

HeartSciences Inc., HSCS, SEC Form 4, Andrew Simpson, stock options, Restricted Stock Units, RSU, equity grant, executive compensation, FDA clearance, MyoVista wavECG, AI-ECG algorithm, corporate governance, insider transaction